HK1203499A1 - Pyrrolo[2,1-f][1,2,4]triazine compound, and preparation method and application thereof [21-f][124] - Google Patents
Pyrrolo[2,1-f][1,2,4]triazine compound, and preparation method and application thereof [21-f][124]Info
- Publication number
- HK1203499A1 HK1203499A1 HK15104065.5A HK15104065A HK1203499A1 HK 1203499 A1 HK1203499 A1 HK 1203499A1 HK 15104065 A HK15104065 A HK 15104065A HK 1203499 A1 HK1203499 A1 HK 1203499A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- pyrrolo
- preparation
- application
- triazine compound
- triazine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210177980.3A CN103450204B (zh) | 2012-05-31 | 2012-05-31 | 吡咯[2,1-f][1,2,4]并三嗪类化合物,其制备方法及用途 |
PCT/CN2013/074559 WO2013177983A1 (zh) | 2012-05-31 | 2013-04-23 | 吡咯[2,1-f][1,2,4]并三嗪类化合物,其制备方法及用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1203499A1 true HK1203499A1 (en) | 2015-10-30 |
Family
ID=49672377
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15104065.5A HK1203499A1 (en) | 2012-05-31 | 2015-04-27 | Pyrrolo[2,1-f][1,2,4]triazine compound, and preparation method and application thereof [21-f][124] |
Country Status (14)
Country | Link |
---|---|
US (1) | US9447101B2 (xx) |
EP (1) | EP2857403B1 (xx) |
JP (1) | JP6067107B2 (xx) |
KR (1) | KR101824299B1 (xx) |
CN (1) | CN103450204B (xx) |
AU (1) | AU2013270326B2 (xx) |
BR (1) | BR112014029708B1 (xx) |
CA (1) | CA2874062C (xx) |
ES (1) | ES2703934T3 (xx) |
HK (1) | HK1203499A1 (xx) |
MX (1) | MX359207B (xx) |
RU (1) | RU2589053C1 (xx) |
SG (1) | SG11201407752YA (xx) |
WO (1) | WO2013177983A1 (xx) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9724352B2 (en) * | 2012-05-31 | 2017-08-08 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof |
EP2948454B1 (en) | 2013-01-24 | 2017-05-31 | Council of Scientific & Industrial Research An Indian registered body incorporated under the Registration of Societies Act (Act XXI of 1860) | Triazine compounds and a process for preparation thereof |
WO2016064957A1 (en) | 2014-10-22 | 2016-04-28 | Bristol-Myers Squibb Company | Bicyclic heteroaryl amine compounds as pi3k inhibitors |
WO2016064958A1 (en) | 2014-10-22 | 2016-04-28 | Bristol-Myers Squibb Company | Heteroaryl substituted pyrrolotriazine amine compounds as pi3k inhibitors |
WO2017004134A1 (en) * | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
WO2017040448A1 (en) * | 2015-08-31 | 2017-03-09 | Bristol-Myers Squibb Company | Tgf beta receptor antagonists |
JP6858252B2 (ja) | 2016-06-25 | 2021-04-14 | スーチョウ キンター ファーマシューティカルズ インコーポレイテッド | ラパマイシンシグナル伝達経路阻害剤のメカニズム標的、及びその治療応用 |
CN109111447A (zh) * | 2017-06-23 | 2019-01-01 | 中国科学院上海药物研究所 | 7-位取代吡咯并三嗪类化合物或其药学上可用的盐,及其制备方法和用途 |
WO2019034076A1 (zh) * | 2017-08-15 | 2019-02-21 | 南京明德新药研发股份有限公司 | Fgfr抑制剂及其医药用途 |
GB201720989D0 (en) * | 2017-12-15 | 2018-01-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
WO2021055747A1 (en) * | 2019-09-19 | 2021-03-25 | Totus Medicines Inc. | Therapeutic conjugates |
AU2021285715A1 (en) * | 2020-06-05 | 2023-01-19 | Monash University | Dual kinase-bromodomain inhibitors |
CN112851563A (zh) * | 2020-12-30 | 2021-05-28 | 安徽金鼎医药股份有限公司 | N-氨基-3-氮杂双环[3,3,0]辛烷盐酸盐的合成工艺 |
WO2023035614A1 (zh) * | 2021-09-10 | 2023-03-16 | 上海海和药物研究开发股份有限公司 | 包含PI3Kα抑制剂的药物组合 |
CN117126164A (zh) * | 2023-08-30 | 2023-11-28 | 山东轩硕医药科技有限公司 | 一种吡咯并三嗪类化合物,其制备方法及用途 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6867300B2 (en) | 2000-11-17 | 2005-03-15 | Bristol-Myers Squibb Company | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors |
TWI329112B (en) | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
TW200420565A (en) | 2002-12-13 | 2004-10-16 | Bristol Myers Squibb Co | C-6 modified indazolylpyrrolotriazines |
MY145634A (en) | 2003-12-29 | 2012-03-15 | Bristol Myers Squibb Co | Pyrrolotriazine compounds as kinase inhibitors |
EP1812439B2 (en) | 2004-10-15 | 2017-12-06 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
US7151176B2 (en) | 2004-10-21 | 2006-12-19 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds |
TW200635927A (en) | 2004-12-22 | 2006-10-16 | Bristol Myers Squibb Co | Synthetic process |
US7232901B2 (en) | 2005-07-01 | 2007-06-19 | Bristol-Myers Squibb Company | Intermediates useful in preparing certain pyrrolotriazine compounds and process for making such intermediates |
US7514435B2 (en) | 2005-11-18 | 2009-04-07 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
DK2041138T3 (da) | 2006-07-07 | 2014-08-11 | Bristol Myers Squibb Co | Pyrroltriazinkinase-inhibitorer |
PT2050749T (pt) * | 2006-08-08 | 2018-01-02 | Chugai Pharmaceutical Co Ltd | Derivado de pirimidina como inibidador de pi3k e sua utilização |
MY180595A (en) * | 2006-12-07 | 2020-12-03 | Genentech Inc | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
WO2008083398A2 (en) | 2007-01-02 | 2008-07-10 | Bristol-Myers Squibb Company | Intermediate useful in preparing certain pyrrolotriazine compounds and a process for making the intermediate |
EP2134716A1 (en) | 2007-04-18 | 2009-12-23 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
US8124759B2 (en) | 2007-05-09 | 2012-02-28 | Abbott Laboratories | Inhibitors of protein kinases |
CA2702838A1 (en) * | 2007-10-16 | 2009-04-23 | Wyeth Llc | Thienopyrimidine and pyrazolopyrimidine compounds and their use as mtor kinase and pi3 kinase inhibitors |
TW200938201A (en) * | 2008-02-07 | 2009-09-16 | Chugai Pharmaceutical Co Ltd | Pyrrolopyrimidine derivative as PI3K inhibitor and use thereof |
US20110269740A1 (en) | 2008-07-02 | 2011-11-03 | Ambit Biosciences Corporation | Jak kinase modulating compounds and methods of use thereof |
WO2010002954A1 (en) * | 2008-07-02 | 2010-01-07 | Wyeth | (2-aryl-7h-pyrrolo[2,3-d]pyrimidin-4-yl)morpholine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
WO2010092340A1 (en) * | 2009-02-13 | 2010-08-19 | Ucb Pharma S.A. | Fused pyridine and pyrazine derivatives as kinase inhibitors |
CA2756759C (en) * | 2009-04-16 | 2017-11-07 | Joaquin Pastor Fernandez | Imidazopyrazines for use as kinase inhibitors |
EP2526102B1 (en) * | 2010-01-22 | 2017-03-08 | Fundación Centro Nacional de Investigaciones Oncológicas Carlos III | Inhibitors of PI3 kinase |
US20130131057A1 (en) * | 2010-05-13 | 2013-05-23 | Centro Nacional De Investigaciones Oncologicas (Cnio | New bicyclic compounds as pi3-k and mtor inhibitors |
CN102675323B (zh) | 2012-06-01 | 2014-04-09 | 南京药石药物研发有限公司 | 吡咯并[2,1-f][1,2,4]三嗪衍生物及其抗肿瘤用途 |
-
2012
- 2012-05-31 CN CN201210177980.3A patent/CN103450204B/zh active Active
-
2013
- 2013-04-23 ES ES13798006T patent/ES2703934T3/es active Active
- 2013-04-23 SG SG11201407752YA patent/SG11201407752YA/en unknown
- 2013-04-23 RU RU2014147863/04A patent/RU2589053C1/ru active
- 2013-04-23 BR BR112014029708-8A patent/BR112014029708B1/pt active IP Right Grant
- 2013-04-23 EP EP13798006.6A patent/EP2857403B1/en active Active
- 2013-04-23 CA CA2874062A patent/CA2874062C/en active Active
- 2013-04-23 KR KR1020147033824A patent/KR101824299B1/ko active IP Right Grant
- 2013-04-23 JP JP2015514329A patent/JP6067107B2/ja active Active
- 2013-04-23 US US14/403,014 patent/US9447101B2/en active Active
- 2013-04-23 MX MX2014014622A patent/MX359207B/es active IP Right Grant
- 2013-04-23 WO PCT/CN2013/074559 patent/WO2013177983A1/zh active Application Filing
- 2013-04-23 AU AU2013270326A patent/AU2013270326B2/en active Active
-
2015
- 2015-04-27 HK HK15104065.5A patent/HK1203499A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
BR112014029708A2 (pt) | 2017-06-27 |
EP2857403A1 (en) | 2015-04-08 |
WO2013177983A1 (zh) | 2013-12-05 |
EP2857403A4 (en) | 2015-10-21 |
JP2015518010A (ja) | 2015-06-25 |
CN103450204A (zh) | 2013-12-18 |
CA2874062C (en) | 2015-09-22 |
US9447101B2 (en) | 2016-09-20 |
US20150141644A1 (en) | 2015-05-21 |
KR20150009565A (ko) | 2015-01-26 |
AU2013270326A1 (en) | 2014-12-18 |
AU2013270326B2 (en) | 2016-07-14 |
ES2703934T3 (es) | 2019-03-13 |
CN103450204B (zh) | 2016-08-17 |
RU2589053C1 (ru) | 2016-07-10 |
JP6067107B2 (ja) | 2017-01-25 |
KR101824299B1 (ko) | 2018-03-14 |
EP2857403B1 (en) | 2018-10-10 |
BR112014029708B1 (pt) | 2023-05-02 |
SG11201407752YA (en) | 2015-01-29 |
MX2014014622A (es) | 2015-08-10 |
CA2874062A1 (en) | 2013-12-05 |
BR112014029708A8 (pt) | 2021-09-08 |
MX359207B (es) | 2018-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1203499A1 (en) | Pyrrolo[2,1-f][1,2,4]triazine compound, and preparation method and application thereof [21-f][124] | |
IL269797B (en) | Antimicrobial solid surfaces and treatments and methods for their preparation | |
EP2727580A4 (en) | COMPOSITION CONTAINING ASTAXANTHIN, METHOD FOR PRODUCING THE SAME, AND COSMETIC PRODUCT THEREOF | |
EP2830152A4 (en) | ANTENNA ASSEMBLY AND METHOD FOR MANUFACTURING THE SAME | |
EP2796442A4 (en) | ANALOG COMPOUND FROM A CAJANINE STRUCTURE, MANUFACTURING METHOD AND USE THEREOF | |
EP2822998A4 (en) | COMPATIBILIZED COMPOSITION, METHOD FOR FORMING THE SAME, AND ARTICLE COMPRISING SAME | |
EP2816012A4 (en) | MONOLITE OF A MACROPOROUS TITANIUM COMPOUND AND METHOD FOR THE PRODUCTION THEREOF | |
PT2797436T (pt) | Métodos para preparação de bebidas à base de plantas | |
GB201208548D0 (en) | Compound and method | |
MY156744A (en) | Antioxidant, antioxidant composition, and method producing the same | |
EP2693564A4 (en) | AMPLIFICATION ANTENNA AND METHOD FOR MANUFACTURING THE SAME | |
EP2763998A4 (en) | TRI-HETEROCYCLIC DERIVATIVES, MANUFACTURING METHOD AND USES THEREOF | |
IL235949A0 (en) | Pyrrolo [2,1-f] [1,2,4] triazine derivative and uses thereof for the treatment of tumors | |
EP3040308A4 (en) | Pentasil-type zeolite, and method for manufacturing same | |
HRP20181326T1 (hr) | Pesticidni pripravak i postupak za njegovu proizvodnju | |
EP2860181A4 (en) | CONDENSED PYRIMIDINE COMPOUND, AND PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND USES OF SAID COMPOUND | |
EP2813495A4 (en) | 2-ARYLBENZOFURAN-7-FORMAMIDE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND USE THEREOF | |
EP2671878A4 (en) | SUBSTITUTED N-PENTANAMIDE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | |
EP2836551A4 (en) | COMPATIBILIZED COMPOSITION, PROCESS FOR FORMATION THEREOF, AND ARTICLE COMPRISING SAME | |
PL2723743T3 (pl) | Pochodne 10H-benzo[g]pterydyno-2,4-dionu, sposób ich wytwarzania i ich zastosowanie | |
EP2669292A4 (en) | RIBOFURANOSYL-PURINE COMPOUND, PROCESS FOR PREPARING THE SAME, AND USE THEREOF | |
IL235805A (en) | Pyrimidinyl-Diazaspiro compound and process for preparation | |
EP2928693A4 (en) | DECORLAMINATE AND METHOD FOR THE PRODUCTION THEREOF | |
EP2778168A4 (en) | PYRROLO-PYRROLEDION-THENCHINONE COMPOUND AND METHOD OF MANUFACTURING THEREOF | |
EP2905274A4 (en) | IMID compound, method for producing the same and use as an insecticide |